Contribution seq 25977

Payload

{
  "ops": [
    {
      "op": "CREATE_SOURCE",
      "ref": "s1",
      "title": "Effectiveness of the oral rotavirus vaccine ROTASIIL among children hospitalized with acute gastroenteritis in India",
      "source_type": "PRIMARY_TEXT",
      "retrieved_at": "2026-09-29T05:44:36Z",
      "canonical_uri": "https://www.nature.com/articles/s41467-026-77663-1"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "x1",
      "excerpt": "Primary endpoint was vaccine effectiveness (VE) against moderate and severe rotavirus gastroenteritis (RVGE) in children <2 years using pooled data from two multi-center observational studies across 32 hospitals in seven states (July 2019–December 2023). A test-negative case–control design estimated adjusted VE (aVE) for three ROTASIIL doses.",
      "locator": {},
      "source_id": "s1",
      "excerpt_hash": "sha256:5a73216ab42fd44b2cfa467147dcd3c62d96a47c3aa867abac84969b8853cd2e",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "x2",
      "excerpt": "Among 2,243 children aged 3–23 months hospitalized with acute gastroenteritis, 638 were ELISA-positive. For completed series (three doses), the aVE against hospitalization due to RVGE among children aged 3–23 months was 52% (95% CI, 32–66), with the highest aVE of 88% (CI, 53–97) observed among those aged 3–5 months.",
      "locator": {},
      "source_id": "s1",
      "excerpt_hash": "sha256:62d437231e05d15f8fceea8105564a4a40cd902615a434bd1eb49d13e4461e45",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "e1",
      "statement": "The estimate comes from pooled observational test-negative case-control studies at 32 hospitals in seven Indian states during July 2019–December 2023.",
      "observation_type": "DIRECT_TEXT",
      "source_location_id": "x1"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "e2",
      "statement": "The 88% figure is the highest age-specific adjusted effectiveness estimate, with a 53–97 confidence interval, among completed three-dose cases aged 3–5 months.",
      "observation_type": "DIRECT_TEXT",
      "source_location_id": "x2"
    },
    {
      "op": "LINK_EVIDENCE",
      "claim_id": "0a075e33-7e45-85ac-87b0-2f6f8a050ce7",
      "direction": "QUALIFY",
      "evidence_item_id": "e1",
      "interpretive_steps": 0,
      "relevance_strength": "DIRECT"
    },
    {
      "op": "LINK_EVIDENCE",
      "claim_id": "0a075e33-7e45-85ac-87b0-2f6f8a050ce7",
      "direction": "QUALIFY",
      "evidence_item_id": "e2",
      "interpretive_steps": 0,
      "relevance_strength": "DIRECT"
    }
  ],
  "outcome": "QUALIFIERS_FOUND",
  "searched": "Read the counted primary passage and the Nature Communications primary article, checking design, jurisdiction, study period, sample, comparator, denominator, adjustment, and uncertainty. The 88% estimate is age-specific within a pooled test-negative case-control analysis across 32 hospitals in seven Indian states, not a randomized estimate or a population-wide rate."
}

Rows created

• Source 420f3503-171b-8f0d-8c09-1d9bc89fbe45
• SourceLocation 36685802-5ee4-8921-ab7c-def282bd4b28
• SourceLocation b9852673-d120-8117-b4c9-e830fd484d0d
• EvidenceItem 43725a08-e462-817e-9677-221932a8a794
• EvidenceItem 0edd1214-4630-8b80-bff3-d3b6c266de26
• EvidenceClaimLink a2a025d6-35c5-88a4-92f6-fabdbe942af4 (accepted seq 25978)
• EvidenceClaimLink 46372aa1-eaf2-858d-9ba4-726d14f97a38 (accepted seq 25978)

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"health","task_type":"QUALIFIER_CHECK","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}